GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)

[1]  Karen S. Fernández,et al.  Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single‐center experience , 2017, Pediatric blood & cancer.

[2]  R. Randall,et al.  Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report , 2015, Sarcoma.

[3]  L. Qin,et al.  Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma , 2015, Sarcoma.

[4]  K. Behbakht,et al.  Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Melissa Martín,et al.  Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas , 2012, Pediatric blood & cancer.

[7]  P. Hingorani,et al.  Gemcitabine, Docetaxel, and Bevacizumab in Relapsed and Refractory Pediatric Sarcomas , 2012, Journal of pediatric hematology/oncology.

[8]  J. Wathen,et al.  Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. , 2012, The oncologist.

[9]  S. Eberhardt,et al.  Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Mora,et al.  Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents , 2011, Pediatric Blood & Cancer.

[11]  M. Martínez-Beneito,et al.  Childhood cancer incidence and survival in Spain. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  P. Leavey,et al.  Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M Beth McCarville,et al.  Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma , 2008, Cancer.

[14]  S. Spunt,et al.  Analysis of prognostic factors in ewing sarcoma family of tumors , 2007, Cancer.

[15]  J. Khoury.  Ewing Sarcoma Family of Tumors , 2005, Advances in anatomic pathology.

[16]  H. Çamlıca,et al.  Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. , 2004, Japanese journal of clinical oncology.

[17]  V. Sondak,et al.  Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Huvos,et al.  Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[20]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[21]  H. Schultz,et al.  Localised Ewing sarcoma/PNET of bone--prognostic factors and international data comparison. , 2002, Medical and pediatric oncology.

[22]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Craft,et al.  Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  John O'Quigley,et al.  An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .

[25]  J. Bloem,et al.  Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities , 1998, Skeletal Radiology.

[26]  W. Gerald,et al.  Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[28]  M. Jenney.  Principles and Practice of Pediatric Oncology , 1994 .

[29]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[30]  E. Gehan,et al.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  S. Wyard,et al.  THE NATURAL DURATION OF CANCER , 1925, Canadian Medical Association journal.

[34]  W. S. Lazarus-Barlow,et al.  THE NATURAL DURATION OF CANCER , 1924, British medical journal.

[35]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[36]  J. Mora,et al.  Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. , 2009, Journal of pediatric hematology/oncology.

[37]  O. Delattre,et al.  Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Ferrari,et al.  Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[40]  D.,et al.  Regression Models and Life-Tables , 2022 .